Cronos Group
About Cronos Group
Cronos Group is a Toronto-headquartered cannabis company backed by tobacco giant Altria Group, which invested CAD $2.4 billion for a 45% stake. The company focuses on innovative cannabinoid research and product development, with operations in Canada and Israel.
Key Facts
- 1Altria Group, maker of Marlboro cigarettes, invested CAD $2.4 billion for a 45% stake in 2019
- 2Invested in Ginkgo Bioworks partnership for fermentation-based cannabinoid production
- 3Operates through subsidiary Peace Naturals, one of the first licensed producers in Canada
- 4Holds strategic cannabis operations in Israel through Cronos Israel
Latest News
CRON Holds Ground Despite Cannabis Sector Volatility
Cronos Group maintains stable trading amid mixed cannabis earnings season, with strong balance sheet positioning company for strategic opportunities.
Cronos Group Pivots Cannabis Strategy Amid Global Market Shifts
CRON adapts business model as international cannabis markets mature, signaling strategic realignment for growth opportunities.
Frequently Asked Questions
Why did Altria invest in Cronos?
Altria, the tobacco giant behind Marlboro, invested in Cronos to gain a foothold in the cannabis industry as a potential growth avenue given declining cigarette sales. The deal gave Cronos significant capital for R&D and expansion.
What is Cronos doing with biosynthesis?
Cronos partnered with Ginkgo Bioworks to develop fermentation-based production of rare cannabinoids, aiming to produce cannabinoids more efficiently than traditional cultivation methods.
More Cannabis Companies in Toronto
Products
- Spinach flower and vapes
- PEACE NATURALS medical
- Lord Jones CBD
Specialties
Company Details
- Location
- Toronto, Canada
- Founded
- 2012
- Publicly Traded
- Yes
- Ticker
- NASDAQ:CRON